Filing Flows › Charles River Laboratories International (CRL) › Q1 2025
Charles River Laboratories International (CRL) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Charles River Laboratories International (CRL) reported revenue of $984M for the first quarter 2025 (Q1 2025), -3% from a year earlier and -2% from the quarter before. Operating margin was 7.6%, net earnings $25.5M (2.6% of revenue).
Charles River Laboratories International, Q1 2025: revenue $984M (-3% year over year), operating margin 7.6%, net earnings $25.5M, operating cash flow $172M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $984M | -2% | -3% |
| Operating profit | $74.7M | — | -41% |
| Net earnings | $25.5M | — | -65% |
| Operating cash flow | $172M | +8% | +32% |
| Free cash flow | $112M | +34% | +121% |
What changed
Revenue was $984.2M in Q1 2025, down 3% year over year and down 2% from the previous quarter. DSA was the largest line at 60% of revenue. DSA lost $12.8M year over year (down 2%), 47% of the total change.
Operating profit was $74.7M, a 7.6% margin (down 4.9 points year over year). Total costs grew 3% against a revenue fall of 3%. The fastest-growing cost line was Other operating costs (+2146%). Net earnings were $25.5M, down 65% year over year. The effective tax rate was 28.1%.
Operating cash flow was $171.7M (up 32% year over year), 663% of net earnings. Non-cash charges added back $120.4M of depreciation and amortization and $13.1M of share-based compensation. Working capital and other items added $12.3M. Capital expenditures of $59.3M left free cash flow of $112.4M.
Questions
What was Charles River Laboratories International's revenue in the first quarter 2025?
Charles River Laboratories International (CRL) reported revenue of $984M for the first quarter 2025 (Q1 2025), -3% from a year earlier and -2% from the quarter before.
Was Charles River Laboratories International profitable in the first quarter 2025?
Operating profit was $74.7M (7.6% of revenue) and net earnings $25.5M.
Source: Charles River Laboratories International 10-Q on SEC EDGAR.